The Dean’s Profile



 Name: Nicholas Robert Lemoine
Field: Molecular Oncology, Gene Therapy and Translational Medicine
Title: Dean and Chief Executive

    Professor of Molecular Oncology, University of London
          Fellow of the Academy of Medical Sciences, UK
          Fellow of the Royal College of Pathologists, UK
Other current positions:
     National Medical Director, UK NIHR Clinical Research Network
     The NIHR Clinical Research Network is the largest and most successful publicly funded research organization to deliver high quality clinical studies for patient benefit in the world. It employs over 11,500 research staff trained to the highest level and last year recruited over 600,000 patients into clinical trials that have the potential to change clinical practice for the better for both patients and health care organisations. Nick is responsible for the appointment, leadership and mentorship of all the medical leaders that contribute so much to this enterprise.

https://www.crn.nihr.ac.uk/about-crn/meet-team/nick-lemoine/

Director, Barts Cancer Institute and Cancer Research UK Centre London UK
The Barts Cancer Institute celebrated its 10th Anniversary in 2015, and is rightly proud of what its staff have achieved in that period. It is ranked in the top 10 University Cancer Institutes in the world, has consistently been the top-performing cancer research organization in the university sector in London and as well as being host to some of the world’s best known scientists and clinicians. The Institute has also attracted a cohort of the most outstanding Early Career Researchers in emerging fields of cancer biology and genomics.

http://www.bci.qmul.ac.uk/staff/item/nick-lemoine

Director of Research & Innovation for Cancer & Surgery, Barts Health NHS Trust, London UK
Barts Health is the largest health provider in the UK, having an inpatient infrastructure of over 2000 beds and serving probably the most socially deprived population in the country. As well as providing the most advanced Acute Trauma Facility with a dedicated air ambulance and rapid access ground transportation infrastructure at the Royal London site, it has the most advanced Cancer and Cardiac Centre in Europe at the Barts site in the City of London.

http://bartshealth.nhs.uk/media/latest-news/2014/april/leading-role-in-clinical-research-gets-underway/

Editor in Chief, Gene Therapy (Nature Specialist Journals)

Chair of Trustees, Medical Research Foundation

http://www.medicalresearchfoundation.org.uk/about-us/board-of-trustees/nicholas-lemoine/

Research Themes:

Bioinformatics, Cancer Genomics, Pancreatic Cancer, Virotherapy and Oncolytic Viruses

Publications:

http://www.ncbi.nlm.nih.gov/pubmed/?term=lemoine_nr

I work with Professor Claude Chelala and Dr Tatjana Crnogorac-Jurcevic on the genomics and molecular pathology of pancreatic cancer. We use global profiling approaches at the genomic and proteomic levels to identify targets that can be exploited for detection and treatment of this disease. We are also developing novel platforms and algorithms for the bioinformatic interrogation and interpretation of very large, multidimensional datasets.

I work with Professor Yaohe Wang and Dr Gunnel Hallden on the development of oncolytic virotherapy, an approach that uses adenoviruses and vaccinia viruses that selectively replicate within and kill cancer cells, but leave normal cells untouched. We are also working on defining the cell survival signalling circuits that determine the sensitivity of cancer cells to this approach. The role of the immune system in modulating viral replication and tumour cell destruction is the focus of a major new programme.

I was Professor of Molecular Pathology at Imperial College London, where I was Director of the Cancer Research UK Molecular Oncology Unit and the first Director of the National Translational Cancer Research Centre at Hammersmith Hospital. Before that, I held academic positions at the Royal Postgraduate Medical School, London and The University of Wales College of Medicine in Cardiff. I originally trained in medicine at St Bartholomew's Hospital Medical College where I qualified with the University of London Gold Medal in 1983, specialising in pathology and oncology with posts in London and Cardiff.

I recently stepped down as Chairman of the MRC Clinical Research & Career Development Panel and the National Institute of Health Research Clinician Scientist Appointments & Review Panel. I previously chaired the MRC Stem Cell Fellowship Panel, the CR-UK Clinician Scientist and Senior Clinician Fellowship Panel and the MRC Experimental Medicine Review Panel for the Molecular & Cellular Medicine Board. I have been a long-serving member of the Gene Therapy Advisory Committee at the Department of Health, as well as CR-UK Science Funding Committee, MRC Molecular & Cellular Medicine Board, CORE Scientific Advisory Board and many other scientific review committees.

I have been the Editor of the Nature Specialist Journal Gene Therapy since 1997, and my research into the molecular genetics of cancer and gene therapy is funded by programme grants from Cancer Research UK. I was elected a fellow of the Academy of Medical Sciences in 2006.

In 2006, I worked together with Dr. Wang Yaohe, appointed professor of Zhengzhou University, to establish the first Sino-British Research Centre for molecular oncology at Zhengzhou University in order to introduce up-to-date research in the field of molecular oncology and gene therapy in China. Ever since then, I have been working closely with young scientists and clinical researchers from Zhengzhou University and we have built upon a research platform with scientists trained to advanced levels in the UK and a cutting edge infrastructure for performing the innovative research in cancer cell and gene therapy. From 2014, the Sino-British Research Centre for molecular oncology is recognized as the first national center for international joint research in cell and gene therapy of Zhengzhou University. This makes a significant contribution to Zhengzhou University for keeping us at the forefront of research in the field and improving the influence and the impact of ZZU in the world.

In April 2015, I am appointed as Dean of Academy of Medical Sciences (AMS) of Zhengzhou University. I firmly believe that with the joint efforts of our word-class team, we can make AMS an institute of international standard in the field of scientific research and talent training.

In April 2015, I am appointed as Dean of Academy of Medical Sciences (AMS) of Zhengzhou University. I firmly believe that with the joint efforts of our word-class team, we can make AMS an institute of international standard in the field of scientific research and talent training.

上一篇:About the Academy of Medical Sciences
下一篇:The Management Structure of AMS